Cencora to Distribute Kite’s CAR T-Cell Therapies in U.S. — Cencora, Inc.

Event summary

Cencora partners with Kite, a Gilead Company, to distribute FDA-approved CAR T-cell therapies Yescarta and Tecartus in the U.S.
Collaboration aims to expand access to therapies at authorized treatment centers, including health systems and community oncology practices.
Cencora’s specialty distribution infrastructure will support order management and reduce administrative burdens.
Cencora ranks #10 on the Fortune 500 with over $300 billion in annual revenue.

The big picture

This partnership underscores the growing importance of specialized distribution networks in the cell and gene therapy space. As CAR T-cell therapies become more prevalent, the ability to efficiently manage logistics and reduce provider barriers will be critical. Cencora’s involvement highlights the strategic value of its infrastructure in supporting the expansion of these complex treatments.

What we're watching

Market Expansion: How Cencora’s distribution capabilities will affect Kite’s ability to scale CAR T-cell therapy access across the U.S.
Operational Efficiency: Whether the partnership can sustain reduced administrative burdens for healthcare providers.
Regulatory Compliance: The pace at which FDA-approved CAR T-cell therapies will be integrated into community oncology practices.